Key result
Cardiac troponin and natriuretic peptides reflect unique pathology of the myocardium and serve as powerful prognostic markers for cardiovascular risk stratification in the dialysis population.
Why the study?
What is the diagnostic utility of cardiac biomarkers (troponin and natriuretic peptides) for cardiovascular risk stratification in dialysis patients?
What is the diagnostic utility of cardiac biomarkers (troponin and natriuretic peptides) for cardiovascular risk stratification in dialysis patients?
Cardiac troponin and natriuretic peptides serve as powerful prognostic markers for cardiovascular risk stratification in dialysis patients.
Answers are grounded in this paper and cite their sources.
Supports biomarker use for dialysis risk stratification; leaves open whether it alters management or outcomes.
Mortality in dialysis patients remains high due to excessive cardiovascular disease burden from coronary artery disease, left ventricular hypertrophy, and heart failure. Thus, cardiovascular risk stratification is an important aspect in managing dialysis patients; it may enable early identification of high-risk patients to optimize therapeutic interventions that may ultimately lower their cardiovascular morbidity and mortality. In particular, serum cardiac biomarkers that are readily measured, inexpensive, reproducible with high sensitivity and specificity, may have potential for cardiovascular risk prediction and stratification. Cardiac troponin represents a highly sensitive and specific marker of myocardial damage and is a current gold standard test for diagnosing acute myocardial infarction in the general population. On the other hand, natriuretic peptides, released from the heart secondary to increased left ventricular wall stress, have emerged as a diagnostic marker for heart failure in the general population. These two biomarkers reflect unique pathology of the myocardium and are powerful prognostic markers in the dialysis population. This article reviews the diagnostic potentials of these two cardiac biomarkers and their clinical application in the dialysis population.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2012) conducted a review in Dialysis patients. Cardiac biomarkers (cardiac troponin and natriuretic peptides) was evaluated. Cardiac troponin and natriuretic peptides reflect unique pathology of the myocardium and serve as powerful prognostic markers for cardiovascular risk stratification in the dialysis population.
Synapse has enriched 10 related papers. Consider them for comparative context: